ADVERTISEMENT
Use of Quantitative Multiplex Immunofluorescence Assay to Detect TROP2 and HER2 Expression
Featuring David Rimm, MD, PhD
David Rimm, MD, PhD, Yale Cancer Center, New Haven, Connecticut, discussed study results which identified quantitative multiplex immunofluorescence assay as an optimal way to detect TROP2 and HER2 expression among patients with breast cancer.
These results were first reported at the 2023 San Antonio Breast Cancer Symposium.
Source:
Robbins C, He M, Khaimova R, et al. Quantitative multiplex immunofluorescence assay for TROP2 and HER2 expression in breast cancer: Towards guiding patient selection for antibody drug conjugate therapiesPresented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract PO3-13-11
© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement